GSTT1,GSTM1,GSTM3andNAT2polymorphisms in laryngeal squamous cell carcinoma in a Greek population

Chatzimichalis, M; Xenellis, John; Tzagaroulakis, Antonios; Sarof, Paulos; Banis, K.; Gazouli, Maria; Bibas, Athanasios

doi:10.1017/s002221510999154x

Cited by 19 publications

(21 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 45 abstracts were retrieved through PubMed and Medline, and 2 additional articles were found through the ISI Web of Knowledge. After reviewing all 47 articles carefully, 16 eligible articles including 2,965 cases with HNC and 3,919 controls were identified and included in the final meta-analysis (19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34). The main characteristics of all 16 studies are described in Table I.…”

Section: Resultsmentioning

confidence: 99%

“…The year of publication of the included studies ranged from 1998 to 2010. There were 11 studies of Caucasians (19,(21)(22)(23)(25)(26)(27)(28)30,31,34), 3 of Asians (24,32,33), 1 of Turkish (20) and 1 of a mixed population (including Caucasian and other mixed populations) (29). All cases of HNC were pathologically confirmed.…”

Section: Resultsmentioning

confidence: 99%

“…Unal et al (48) and Lei et al (49) also found that the NAT2 slow acetylator phenotype may increase the risk of susceptibility to laryngeal carcinoma. Among the 16 studies included in this meta-analysis, 2 studies suggested that the NAT2 rapid phenotype was associated with the risk of HNC (19,20), whereas 1 study suggested that it acted as a protective factor for HNC (34). In the remaining 13 studies, no significant association was found between NAT2 phenotypes and cancer risk.…”

Section: Discussionmentioning

confidence: 98%

See 2 more Smart Citations

Association of NAT2 phenotype with risk of head and neck carcinoma: A meta-analysis

Zheng

Teng

et al. 2011

Oncology Letters

View full text Add to dashboard Cite

Abstract. N-acetyltransferase 2 (NAT2) is a key enzyme involved in the metabolism of xenobiotics and plays a significant role in the detoxification of numerous potential carcinogens. According to its acetylation status, NAT2 acetylator may be classified into two phenotypes, rapid and slow. Numerous studies have demonstrated that the polymorphisms of NAT2 were correlated with individual susceptibility to several malignant neoplasms, including head and neck carcinomas (HNC). However, the associations between the acetylator phenotypes and HNC risk in each study were not entirely consistent. To assess these associations more comprehensively, we performed a meta-analysis. In this meta-analysis, 16 eligible studies including 2,965 cases with HNC and 3,919 controls were identified by searching the databases of PubMed, Medline and the ISI Web of Knowledge. Odds ratios (ORs) with 95% confidence intervals (95% CIs) were used to evaluate the association. No significant associations between the rapid acetylator phenotype in NAT2 and HNC risk were found either in the overall analysis (OR=0.98; 95% CI 0.83, 1.15; I 2 =57%; P heterogeneity =0.003) or in the subgroup analysis by ethnicity (for the Caucasian population, OR=1.03, 95% CI 0.85, 1.24, I 2 = 63%, P heterogeneity = 0.002; for other mixed populations, OR=0.78, 95% CI=0.61, 1.00, I 2 = 0%, P heterogeneity =0.47). In conclusion, this meta-analysis suggested that there is no association between the NAT2 phenotype and the risk of HNC. IntroductionHead and neck carcinoma (HNC), arising from the sites of the oral cavity, oropharynx, hypopharynx and larynx, is the sixth most common type of cancer worldwide (1). It is characterized by a moderately low survival rate, a high recurrence rate, and a high rate of second primary malignancy (2). In 2009, approximately 49,260 new cases (35,530 males and 13,730 females) of HNC were diagnosed in the USA, and 11,480 deaths occurred (8,300 males and 3,180 females) (1). Present evidence has proven that numerous factors contribute to the risk of squamous cell carcinoma of the head and neck, including tobacco use, alcohol consumption (3), viral infection (4) and genetic polymorphisms (5). In particular, tobacco smoking and alcohol consumption account for approximately 80% of HNC cases (6,7). However, it is worth noting that only a fraction of smokers and alcohol consumers develop HNC. This phenomenon suggests that host factors, including genetic variation, contribute to the inter-individual variation in the susceptibility to HNC.Numerous procarcinogens are known to exist in tobacco, including polycyclic aromatic hydrocarbons (PAHs), aromatic and heterocyclic amines; nitroso-compounds in smoking tobacco; and nitrosamines, aromatic and heterocyclic amines in smokeless tobacco. Most of these carcinogens generally undergo bioactivation and inactivation by phase Ⅰ and Ⅱ enzymes, respectively. The phase Ⅱ enzymes, including Glutathione S-transferases (GSTs) and N-acetyltransferase (NAT), contribute to the detoxification metabolism. Human NAT compr...

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Association of NAT2 phenotype with risk of head and neck carcinoma: A meta-analysis

Zheng

Teng

et al. 2011

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Activated or hypersensitive factors related to the procedure of oncogenesis could produce a rapid reaction to smoking, cancer recurrence or second primary tumors. Such factors could be HPV (Human Papilloma Virus), oncogenetic genes or stem cells [20,21,22,23,24,25,26,27,28]. …”

Section: Discussionmentioning

confidence: 99%

“…Indeed, there is evidence suggesting that alterations of detoxication enzymes, such as glutathione S-transferases and N-acetyltransferases, influence the risk of cancers associated with tobacco and alcohol consumption [20]. Rohrer et al [21 ]correlated both lung cancer and HNC to the upregulation of nuclear factor kappa B.…”

Section: Discussionmentioning

confidence: 99%

Continuation of Smoking after Treatment of Laryngeal Cancer: An Independent Prognostic Factor?

Kikidis

Vlastarakos

Manolopoulos

et al. 2012

ORL

View full text Add to dashboard Cite

Aim: The aim of the study is to examine if continuation of smoking after treatment is an independent factor affecting the prognosis of laryngeal cancer. Materials and Methods: A total of 153 patients met the inclusion criteria for this prospective study, and they were followed up for 12–60 months. Smoking cessation/continuation rates were recorded and associated with disease recurrence and overall patient survival. Results: The recurrence rate was 35.29%. Twenty-five percent of the patients continued smoking after treatment, 75% stopped. Of the patients who quit smoking, 28.69% died during the follow-up period, compared to 52.63% of those who continued (p = 0.0047). The respective recurrence rates were 28.7 and 55.26% (p = 0.0022). A stepwise multivariate Cox regression analysis eliminated potential confounders regarding the overall survival rate and confirmed that time between symptom onset and diagnosis, T and N stage and continuation of smoking after treatment are statistically significant factors. Among them, continuation of smoking was found to have the strongest correlation to the overall survival rate. Conclusion: Continuation of smoking after treatment of laryngeal cancer is an independent negative prognostic factor. From a clinical standpoint, all patients with known laryngeal cancer should be strongly encouraged to quit smoking.

show abstract

Quantitative assessment of the association between GSTM1 null genotype and laryngeal cancer risk

Xiao

Tian

et al. 2012

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

Previous studies investigating the association between glutathione S-transferase M1 (GSTM1) null genotype and laryngeal cancer risk reported controversial results. Thus, a meta-analysis was performed to clarify the effect of GSTM1 null genotype on laryngeal cancer risk. A literature search was performed for all possible studies. We estimated summary odd ratio (OR) with its 95 % confidence interval (95 % CI) to assess the association. Subgroup analyses were performed by ethnicity or the sample size. 24 individual case-control studies involving a total of 2,809 laryngeal cancer cases and 4,478 controls were finally included into this meta-analysis. Meta-analyses of total 24 studies showed the GSTM1 null genotype was significantly associated with increased laryngeal cancer risk (random-effects OR = 1.44, 95 % CI 1.19-1.73, P < 0.001). Subgroup analyses by ethnicity showed that the GSTM1 null genotype was associated with increased laryngeal cancer risk in both Caucasians (fixed-effects OR = 1.17, 95 % CI 1.04-1.33, P = 0.012) and Asians (random-effects OR = 1.89, 95 % CI 1.28-2.77, P = 0.001). Also, subgroup analyses by sample size also further identified this association above. The cumulative meta-analyses showed a trend of more obvious association between GSTM1 null genotype and increased risk of laryngeal cancer as information accumulated by year. Meta-analysis of available data suggests that GSTM1 null genotype contributes to increased laryngeal cancer risk in both Caucasians and East Asians.

show abstract

GSTT1,GSTM1,GSTM3andNAT2polymorphisms in laryngeal squamous cell carcinoma in a Greek population

Abstract: This study demonstrated a significant relationship between rapid acetylator genotypes and laryngeal squamous cell carcinoma in a Greek population.

Cited by 19 publications

References 17 publications

Association of NAT2 phenotype with risk of head and neck carcinoma: A meta-analysis

Association of NAT2 phenotype with risk of head and neck carcinoma: A meta-analysis

Continuation of Smoking after Treatment of Laryngeal Cancer: An Independent Prognostic Factor?

Quantitative assessment of the association between GSTM1 null genotype and laryngeal cancer risk

Contact Info

Product

Resources

About